14.90
0.68 (4.78%)
| Previous Close | 14.22 |
| Open | 13.91 |
| Volume | 645,197 |
| Avg. Volume (3M) | 6,832,288 |
| Market Cap | 2,767,822,592 |
| Price / Sales | 20.16 |
| Price / Book | 20.03 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Profit Margin | -107.04% |
| Operating Margin (TTM) | -542.82% |
| Diluted EPS (TTM) | -0.750 |
| Quarterly Revenue Growth (YOY) | -26.80% |
| Total Debt/Equity (MRQ) | 13.13% |
| Current Ratio (MRQ) | 2.95 |
| Operating Cash Flow (TTM) | -180.63 M |
| Levered Free Cash Flow (TTM) | -133.93 M |
| Return on Assets (TTM) | -30.02% |
| Return on Equity (TTM) | -105.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Wave Life Sciences Ltd. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.75 |
|
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 16.25% |
| % Held by Institutions | 84.41% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (Truist Securities, 235.57%) | Buy |
| Median | 33.00 (121.48%) | |
| Low | 27.00 (RBC Capital, 81.21%) | Buy |
| Average | 36.27 (143.42%) | |
| Total | 11 Buy | |
| Avg. Price @ Call | 17.63 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 05 Feb 2026 | 41.00 (175.17%) | Buy | 13.33 |
| 09 Dec 2025 | 34.00 (128.19%) | Buy | 21.31 | |
| Canaccord Genuity | 03 Feb 2026 | 43.00 (188.59%) | Buy | 13.70 |
| 09 Dec 2025 | 40.00 (168.46%) | Buy | 21.31 | |
| HC Wainwright & Co. | 19 Dec 2025 | 30.00 (101.34%) | Buy | 15.98 |
| Oppenheimer | 16 Dec 2025 | 32.00 (114.77%) | Buy | 16.41 |
| Truist Securities | 15 Dec 2025 | 50.00 (235.57%) | Buy | 16.11 |
| B. Riley Securities | 12 Dec 2025 | 37.00 (148.32%) | Buy | 16.56 |
| Wedbush | 12 Dec 2025 | 33.00 (121.48%) | Buy | 16.56 |
| 11 Nov 2025 | 20.00 (34.23%) | Buy | 7.26 | |
| Citigroup | 09 Dec 2025 | 30.00 (101.34%) | Buy | 21.31 |
| Clear Street | 09 Dec 2025 | 47.00 (215.44%) | Buy | 21.31 |
| RBC Capital | 09 Dec 2025 | 27.00 (81.21%) | Buy | 21.31 |
| Wells Fargo | 09 Dec 2025 | 29.00 (94.63%) | Buy | 21.31 |
| 11 Nov 2025 | 16.00 (7.38%) | Buy | 7.26 | |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |